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ABSTRACT
Mixed cryoglobulinemia syndrome (MC) is a systemic vasculitis involving kidneys, 
joints, skin, and peripheral nerves. While many autoimmune, lymphoproliferative, 
and neoplastic disorders have been associated with this disorder, hepatitis C virus 
(HCV) is known to be the etiologic agent in the majority of patients. Therefore, clinical 
research has focused on anti-viral drugs and, more recently, on the new, highly 
potent Direct-acting Antiviral Agents (DAAs). These drugs assure sustained virologic 
response (SVR) rates >90%. Nevertheless, data on their efficacy in patients with HCV-
associated cryoglobulinemic vasculitis are disappointing, possibly due to the inability 
of the drugs to suppress the immune-mediated process once it has been triggered. 
Despite the potential risk of exacerbation of the infection, immunosuppression 
has traditionally been regarded as the first-line intervention in cryoglobulinemic 
vasculitis, especially if renal involvement is severe. Biologic agents have raised 
hopes for more manageable therapeutic approaches, and Rituximab (RTX), an anti 
CD20 monoclonal antibody, is the most widely used biologic drug. It has proved to 
be safer than conventional immunosuppressants, thus substantially changing the 
natural history of HCV-associated cryoglobulinemic vasculitis by providing long-term 
remission, especially with intensive regimens. 
The present review focuses on the new therapeutic opportunities offered by the 
combination of biological drugs, mainly Rituximab, with DAAs.
INTRODUCTION
Mixed cryoglobulinemia syndrome (MC) is an 
idiopathic or secondary vasculitis characterised by the 
presence of mixed cryoglobulins in the circulation, 
and deposition in target organs. MC may be associated 
with several conditions including chronic infections, 
lymphoproliferative disorders, connective tissue diseases, 
or non-infectious hepatobiliary conditions. Mixed 
cryoglobulins are cryoprecipitable immune complexes 
consisting either of a monoclonal immunoglobulin (Ig), 
usually an IgM-k, plus a polyclonal Ig-k or lambda (type 
II cryoglobulins), or two polyclonal Igs (type III). In a 
considerable number of patients previously classified as 
type III the more advanced immunofixation techniques 
allow recognition of an intermediate clonal restriction in 
which an oligoclonal Ig is complexed with a polyclonal Ig 
type (type II/III cryoglobulins) [1]. 
Most of the cases that were previously described 
as “idiopathic or essential” are now associated with 
Review
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the presence of hepatitis C virus (HCV) infection [2-
7]. Circulating (usually asymptomatic) cryoglobulins 
are detectable in up to 40% of patients with chronic 
hepatitis C. A specific cryoglobulinemic syndrome 
occurs in a minority of cases (1-2%) [1]. Long-term HCV 
infection, older age and genetic background all represent 
predisposing factors for the development of MC [1,8,9]. 
Renal manifestations involve only 0.1-0.2% of 
HCV-infected, but the presence of glomerulonephritis is a 
major long-term prognostic factor for MC. 
RELEVANT PATHOGENIC ASPECTS 
INVOLVED IN THE CHOICE OF THERAPY 
As well as infecting hepatocytes, HCV also infects 
B-lymphocytes, macrophages, peripheral dendritic cells 
and monocytes [10]. More specifically, HCV-RNA, HCV 
NS3 and core proteins have been restrictively found 
in CD19-positive B cells [11]. HCV-persistent viral 
stimulation enhances the expression of lymphomagenesis-
related genes and may induce a poly- and subsequently 
monoclonal expansion of B-cells [12]. Under this trigger 
effect, permanent clones of B-lymphocytes produce 
oligo- or monoclonal IgM that are known to display 
rheumatoid factor activity, favouring the formation of 
immune-complexes (ICs) formed by the monoclonal IgM 
itself, HCV, and anti-HCV polyclonal IgG antibodies. 
The erythrocyte transport system does not recognize the 
cryoprecipitable ICs because of the clonally restricted IgM 
[13]. Therefore, these ICs escape the splenic and hepatic 
macrophage removal system [14]. Similarly, monocytes 
accumulating in the glomeruli of patients with MC are 
Figure 1: This picture shows the main features of cryoglobulinemic nephritis. Light microscopy: Upper left side 
membranoproliferative pattern. Many loops contain pale eosinophilic material consistent with cryoglobulins. Upper right side higher 
power magnification showing double contour formation. Immunofluorescence (lower left side): subendothelial and mesangial deposition 
of immune reactants. Electron Microscopy (lower right side): structured appearance of electron dense deposits. 
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not able to process internalised ICs, thus potentially 
perpetuating glomerular damage [14]. In a murine model 
of MC-membranoproliferative glomerulonephritis, 
macrophage depletion protects animals from 
glomerulonephritis without affecting cryoglobulin 
removal [15]. This is consonant to the observation that 
macrophage-driving mesangial expansion and activation 
are sustained by the release of pro-inflammatory cytokines 
and pro-cathepsin D from damage-associated molecular 
patterns-activated macrophages (Table 1) [16].
Based on these pathogenic principles it seems 
unlikely that pure antiviral agents can effectively interfere 
with the pathogenesis of MC vasculitis and impact the 
development of the immune-mediated injury once the 
immune process is definitively triggered.
MC-related glomerulonephritis
Table 2 summarises clinical presentations. Renal 
biopsy should be performed in any patient with urinary 
abnormalities, unexplained renal impairment or both. 
Quality and degree of the histological features, which 
do affect therapy, are clinically unpredictable making 
examination of renal specimens by light microscopy, 
immunofluorescence and electron microscopy mandatory. 
Analysis by light microscopy allows the 
identification of three main glomerular patterns 
of cryoglobulin glomerular deposition (Figure 1) 
(summarised in [17]).
Diffuse Membranoproliferative Glomerulonephritis 
(GN) (seen in up to 80% of patients). Typical 
immunohistological findings include 1. duplication of 
glomerular basement membrane, 2. interposition by 
mesangial cells and mainly mononuclear leukocytes/
macrophages, 3. subendothelial and mesangial deposition 
of immune reactant, 4. proliferation and expansion of the 
mesangium and intracapillary leukocyte accumulation, 
with endoluminal hyaline pseudothrombi (corresponding 
to cryoglobulin precipitates). More than 50 % of glomeruli 
are usually affected. Extracapillary proliferation and 
necrosis of the glomerular tuft may occasionally be 
observed.
Focal Membranoproliferative Glomerulonephritis 
(seen in up to 10% of patients). Immunohistological 
findings are similar to the previously described features, 
but are found in less than 50 % of glomeruli. Endoluminal 
thrombi are rarely seen. 
Mesangial Proliferative Glomerulonephritis 
(10% of patients). Typical immunohistological findings 
include diffuse mesangial expansion and proliferation in 
the absence of endocapillary proliferation or exudation. 
Endoluminal thrombi are rare.
Immunofluorescence staining shows diffuse pseudo-
linear mesangial deposition of IgM, IgG, and C3, with a 
relatively stronger staining for IgM and k (as compared 
to lambda) light chain (Figure 1) affecting the peripheral 
capillary wall. Strong IgM and IgG deposition is observed 
in the thrombi, while fibrinogen can be detected in the 
vessel walls as a result of a vasculitic process.
Electron-dense deposits can be detected by electron 
microscopy in the subendothelial and mesangial areas 
along with interposition of the glomerular basement 
membrane by monocytes. Cryoglobulin deposits are 
organised in curved, short, thick-walled tubular structures 
(diameter of about 30 nm) which appear circular on cross 
sections (Figure 1). 
It must be emphasised that the same clinical weight 
cannot be assigned to all histological patterns. Thus, the 
results of clinical studies which are not based on a careful 
histological examination should be evaluated with caution. 
Table 1: Pathogenetic scenario of cryoglobulinemic nephritis (Ref #42)
Pathogenetic scenario of cryoglobulinemic nephritis
Chronic stimulation by HCV infection sustaining the synthesis of IgM rheumatoid factor  (and consequently of 
cryoprecipitable ICs)
Abnormal kinetics and tissue deposition of the HCV-containing ICs
Ineffective cryoglobulin clearance by monocyte/macrophages, which are implicated in perpetuating glomerular damage.
Abbreviations are: ICs, immune complexes
Table 2: Clinical presentations of patients with cryoglobulinemic glomerulonephritis (Ref #7)
Clinical presentations of patients with cryoglobulinemic glomerulonephritis
Isolated proteinuria (<3 g/24 h), usually with microscopic hematuria (30%)
Nephrotic syndrome (20%)
Acute nephritic syndrome (15%). Some patients present with a mixed nephrotic and nephritic syndrome.
Macroscopic hematuria (10%) 
Chronic renal insufficiency  (10%)  
Acute renal failure (10%) 
Oligoanuria (5%) 
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PROGNOSTIC FACTORS
Cryoglobulinemic vasculitis bears significant 
morbidity and mortality. Renal involvement has 
traditionally been considered one of the worst prognostic 
factor [18]. More recently, Terrier and co-workers showed 
that the 1-year, 3-year, 5-year, and 10-year survival rates 
in HCV-positive patients with MC-vasculitis were 96%, 
86%, 75%, and 63%, respectively [19]. Severe infections 
and end-stage liver disease were the main determinants of 
fatal events. Baseline parameters associated with a poor 
prognosis included the presence of severe liver fibrosis 
(Metavir fibrosis score ≥ 3; hazard ratio [HR] 5.31), heart 
involvement (HR 4.2), CNS involvement (HR 2.74), and 
renal involvement (HR 1.91) [19]. The Five-Factor Score 
(FFS) [20], a vasculitis scoring system based on 5 clinical 
variables (serum creatinine>140 μmol/L, proteinuria > 1 
g/d, cardiomyopathy, severe gastrointestinal involvement, 
and central nervous system involvement), was used as 
parameter of poor outcome, and results were confirmed 
by multivariate analysis [20]. Similarly, severe fibrosis 
(HR 10.8) negatively impacted overall survival [20]. 
In a large, multicenter study on HCV-related MC, our 
group demonstrated that significant prognostic variables 
affecting the outcome of therapy included male gender, 
age, proteinuria and creatinine assessed at renal biopsy, 
the number of relapses, and poor blood pressure control 
[1]. Basal creatinine values >1.5 mg/dL (133 μmol/L) 
significantly impacted on survival as shown by Kaplan-
Meier curves analysis. Cardiovascular disease was found 
to be the cause of death in over 60% of cases [1]. 
In a survey from the French CryoVas study, Terrier 
at al. [21] observed that purpura [HR 3.35 (1.02-10.97)], 
cutaneous necrosis [HR 4.46 (1.58-12.57)] and articular 
involvement [HR 2.20 (1.00-4.78)] were significantly 
associated with early relapse. 
Figure 2: Skin ulcers healing after Rituximab treatment.
Figure 3: HCV RNA serum load as evaluated at 0, 3, 6, 9, 12 and 18 months and then yearly after Rituximab 
administration in our cohort of 31 patients with severe mixed cryoglobulinemic vasculitis (type II in 29 cases and type 
III in 2) with diffuse membranoproliferative glomerulonephritis (#16 cases), peripheral neuropathy (#26) and large 
skin ulcers (#7).
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Conventional treatment of cryoglobulinemic 
vasculitis
Although the viral aetiology of MC is now 
unquestionable, immunosuppression is still considered 
the first-line therapeutic approach in MC vasculitis, 
particularly when kidney involvement is severe [21]. 
In fact, antiviral treatment often lacks efficacy and 
might risk being harmful in patients with severe renal 
involvement [17]. Many centres, despite the absence of 
properly designed prospective trials, treat patients with 
Figure 4: Representative dot-plots of Treg(CD4+CD25+FOXP3+, top plots), B cell (CD 20+, central plots) and 
activated T CD8+ cell (CD 20+, lower plots) as evaluated by flow cytometry. Samples from a responder patient analysed 
before and at 6 and 12 months after Rituximab administration. Upon detection of B cell depletion, a 9-fold increase in the circulating 
Treg(CD4+CD25+FOXP3+) and a 7.5-fold decrease in activated T CD8+ cells were observed over 12 months, suggesting Rituximab-
induced Th1 cell resetting. 
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Table 3: Study characteristics and clinical outcome of rituximab-treated patients with mixed cryoglobulinemia (MC) 
reported in the literature
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plasmapheresis, high-dose glucocorticoids, and cytotoxic 
agents for the management of more severe cases. These 
strategies may potentially lead to an increase in viremia 
and an exacerbation of chronic HCV hepatitis. However, 
kidney involvement is often a critical indication for 
these approaches. Another indication remains peripheral 
neuropathy although it is known to be refractory to 
treatment in severe cases. In clinical practice, oral (1.5-
2 mg/kg/day for 3 months), or intravenous (0.5-1 g 
every 2-4 weeks) cyclophosphamide, together with oral 
glucocorticoids (0.5-1 mg/kg/day for 30 days, then tapered 
by 2.5-5 mg/week), usually preceded by intravenous 
methylprednisolone (e.g. 3 infusions of 10-15 mg/kg) is 
the most common regimen for severe manifestations of 
MC [22]. An alternative immunosuppressive choice may 
be the administration of mycophenolate mofetil (a less 
toxic medication) for 6 months. Cyclosporine is known to 
inhibit the polymerase binding to viral RNA [23] and to 
significantly reduce viremia within months. 
Plasma exchange, mainly double-filtration 
plasmapheresis, is still being used successfully in 
escalation protocols for the managements of the more 
*calculated on those with renal involvement; PCS, prospective cohort study, RCT, randomized controlled trial; CS, cross-
sectional, SD, standard deviation; Peg-IFN-α, pegylated interferon-α; RBV, ribavirin; MPGN, membranoproliferative 
glomerulonephritis; UTI, urinary tract infections; CR, complete response, PR, partial response, NR, no response; N/A, not 
applicable. **the rate of renal involvement is not detailed in the 48 evaluable patients;
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severe manifestations of MC (hyperviscosity syndrome, 
glomerulonephritis, cutaneous ulcers, systemic vasculitis, 
and mixed neuropathy). Carrying out an aphaeresis every 
other day for fifteen days followed by one procedures/ a 
week for 2 weeks and one procedure a week for a month 
is the currently recommended schedule [24].
Mixed cryoglobulinemia as a unique pathologic 
condition supporting the therapeutic use of the 
anti-CD20 monoclonal antibody Rituximab
Of the many biologic agents that have shown 
promising results in the management of patients with 
severe vasculitis Rituximab (RTX) is the one that has been 
used extensively to treat mixed cryoglobulinemia [25-40]. 
Rituximab is a humanised chimeric mouse 
monoclonal antibody directed at the lymphocyte 
membrane protein CD20, and it selectively depletes the 
CD20+ B lymphocytes, thereby abolishing IgM production 
and new cryoglobulin formation. It is noteworthy that 
HCV proteins and RNA have been restrictively detected 
in these cells [11]. Presently, more than 400 Rituximab-
treated patients with mixed cryoglobulinemia have 
been reported in the literature. Table 3 summarises the 
published literature regarding the use of Rituximab 
in MC. Briefly, Rituximab has been efficacious in the 
management of the clinical manifestations of MC. Of 
note, it improved skin ulcers, renal manifestations in 75-
90% of cases (usually within three months), and sensitive-
motor neuropathy in 70% of cases. Our group also showed 
that mixed peripheral neuropathy improved within 5 
months after administering Rituximab [32]. Moreover, 
Rituximab treatment has been found to deplete bone 
marrow B-cell clonal expansion resulting in a decrease 
of serum cryoglobulins and rheumatoid factor, and in a 
normalisation of C4 levels [41-45]. 
We recently carried out a very long term 
prospective (mean follow-up 72.47 months), single-
center open study and evaluated the very long-term 
effects of Rituximab administration in patients with 
severe cryoglobulinemic vasculitis [46]. Rituximab 
was given to 31 patients (27 HCV+ve) with mixed 
cryoglobulinemia (type II in 29 subjects and type III in 
2) and diffuse membranoproliferative glomerulonephritis 
(16 cases), sensitive-motor neuropathy (26 cases) and 
severe skin ulcers (7 cases). Rituximab was given at a 
dose of 375 mg/m2 (days 1, 8, 15 and 22, followed by 2 
more doses 1 and 2 months later, the so-called “4 plus 2 
protocol”). Five patients also received 3 pulses of 500 mg 
of methylprednisolone. No other immunosuppressive or 
antiviral drugs were added. We found complete remission 
of pre-treatment active manifestations in all cases of 
purpuric lesions and non-healing vasculitic ulcers (Figure 
2), and in 80% of the peripheral neuropathies. Follow-
up after the second month of Rituximab administration 
revealed a significant improvement in cryoglobulinemic 
nephropathy, and furthermore, cryoglobulinemic 
serological parameters, such as low complement C4 
and cryocrit also improved. No major side effects were 
reported. Re-induction with Rituximab was carried out in 
9 relapsing patients after a mean of 31.1 months (12-54), 
resulting again effective. After 6 years of follow-up, the 
survival rate was 75% and the probability of remaining 
symptom-free for 10 years without any therapy was 
approximately 60% after a single “4 plus 2” infusion 
cycle, while the likelihood of living symptom-free for 
5 years after relapse was 80% if treated with the same 
protocol. Six patients in this study (mean age 75.3 yrs.) 
died of cardiovascular causes a median of 55 months after 
their RTX cicle [46]. This open, prospective study showed 
Rituximab to be safe and effective for treating the most 
severe cases of MC, even in a very long-term perspective 
(6 years). 
In order to evaluate the available data regarding 
the use of Rituximab in cryoglobulinemic vasculitis with 
a particular focus on cryoglobulinemic nephropathy, 
we searched MEDLINE and EMBASE using the terms 
“rituximab” and “cryoglobulinemia” in publications 
between January 1, 1999, to April 1, 2016. Studies were 
included if they were randomised, controlled studies 
(RCT) or case series with more than 10 adult patients. 
Studies were excluded 1. if they were reviews or expert 
comments or case series with fewer than 10 patients; 
2. if the main outcome was not clinical, and 3. if they 
were published in abstract form alone. When several 
publications involving the same group of patients were 
found, only the most recent and comprehensive paper 
was considered unless the publication was derived from 
another patient cohort or if the number of included patients 
was significantly higher.
Among the 233 identified publications, 19 
studies met the inclusion criteria, with 16 open-label 
trials [22-37] and 3 RCTs [38-40]. Selected items were 
systematically searched for in each paper, i.e., the number 
of included patients, duration of follow-up, indication 
for treatment with Rituximab and dosage, concomitant 
immunosuppressive treatment, corticosteroid dosage and 
clinical and biological outcomes.
Sixteen open-label trials [22-37], each of which 
having at least 10 patients with cryoglobulinemia treated 
with Rituximab, met the inclusion criteria. Data from a 
total of 440 patients were retrieved. The main indications 
for treatment with Rituximab were skin involvement (skin 
vasculitis, purpura and/or skin ulcers) (N=272, 62%), 
neuropathy (N=254, 58%), and nephropathy (N=143, 
33%). Patients received varying doses of Rituximab 
(2 × 1 g, 4 × 375 mg/m2, 4 +2 × 375 mg/m2 or 2 ×375 mg/
m2), as shown in Table 3. Median complete remission 
(CR) was 68%, partial remission (PR) was 14%, and no 
response was 10%, respectively. 
A further analysis was carried out on case series 
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reporting renal outcomes [23-27,30,32-36] (Table 3). 
These trials included 143 patients, but only a minority 
had biopsy-proven evidence of cryoglobulinemic 
glomerulonephritis. Median rates of renal CR and PR 
and no response to Rituximab in patients with renal 
involvement in cryoglobulinemia were 57%, 20% and 
40%, respectively. Outcomes (overall and renal CR+PR) 
were defined according to the definitions of each study. 
Three RCTs were retrieved [38-40]. In 2010, 
Dammacco and co-workers [38] investigated the safety 
and efficacy of a combined use of pegylated interferon-α 
and ribavirin (RBV), with or without Rituximab, in HCV-
related MC. Twenty-two patients with HCV-related MC 
received pegylated interferon-α (2a: 180 μg or 2b: 1.5μ 
/kg) weekly plus ribavirin (1,000 or 1,200 mg) daily for 
48 weeks, and Rituximab (375 mg/m2) once a week for 1 
month followed by two 5-monthly infusions [38]. Fifteen 
additional patients received pegylated interferon-αI and 
ribavirin with the same modalities, but without Rituximab. 
CR was achieved in 54.5% (12/22) and in 33.3% (5/15) 
of patients who received Rituximab and pegylated 
interferon-α and ribavirin, respectively (p< 0.05), showing 
that as an add-on to antiviral therapy, Rituximab was well 
tolerated and more effective than pegylated interferon-α/ 
ribavirin alone in HCV-related MC.
A prospective RCT investigating the use of 
Rituximab therapy in patients with severe MC was carried 
out by De Vita and colleagues [40]. Fifty-nine patients 
with MC were randomized to the non-Rituximab group 
(receiving conventional treatment consisting of 1 of the 
following 3 options: glucocorticoids; azathioprine or 
(cyclophosphamide; plasmapheresis) or to the Rituximab 
group receiving 2 infusions of 1 g each and lowering 
the glucocorticoid dosage when possible, and with a 
second course of Rituximab at relapse) [40]. Rituximab 
appeared to be the best therapy for all 3 target-organ 
manifestations (skin ulcers, active glomerulonephritis, or 
refractory peripheral neuropathy). The median duration 
of response to Rituximab was 18 months. The number 
of patients who achieved the primary endpoint (survival 
of treatment, defined as the proportion of patients who 
continued taking their initial therapy), was statistically 
higher in the Rituximab group at 1 year (64.3% versus 
3.5%, p<0.0001), as well as at 2 years (60.7% versus 
3.5%, p<0.0001).
In the same year, Sneller and co-workers [39] 
published the results of a single-center, open label, RCT. 
Rituximab (375 mg/ m2/week for 4 weeks) was compared 
to the best available therapy in patients affected by HCV-
associated cryoglobulinemic vasculitis in whom antiviral 
was not effective. Sneller’s group enrolled 24 patients (12 
in each treatment group). Six months after the beginning 
of the treatment ten patients in the rituximab group 
(83%) and 1 patient in the control group (8%) were in 
remission (p< 0.001). The median duration of remission 
for Rituximab-treated patients who reached the remission 
within 6 months was 7 months. Moreover, Sneller’s group 
did not observe any adverse effects of Rituximab on HCV 
viremia or on the liver.
When focusing on the renal clinical outcome, our 
review of the literature showed a very heterogeneous 
response to Rituximab. Our recently published study, 
which represents the largest single-center cohort of 
patients with MC and renal involvement prospectively 
treated with Rituximab [41] , showed a greater than 90% 
rate of any response (CR+PR) at the end of follow-up. 
We retrieved 11 studies with reported renal 
outcomes. The median complete response rate was 
57% (vs. 75% in our cohort). It may be speculated that 
the “4 plus 2 (improved) protocol might intensify the 
depleting effect of Rituximab on lymphocytes when 
compared to other Rituximab regimens, thus maintaining 
more prolonged B-cell depletion and improving clinical 
outcome [45]. 
MC is an immune-mediated process that becomes 
independent from the triggering virus. Rituximab is much 
more selective than conventional immunosuppressive 
treatments at interfering with the downstream processes 
following the disease trigger [41-43], and is definitely 
safer, as shown in Figure 3 which summarises the data 
of HCV RNA serum load after Rituximab administration 
in our cohort of 31 patients with severe mixed 
cryoglobulinemic vasculitis. Moreover, MC-associated 
nephritis exemplifies a unique condition of immune-
mediated conditions in which Rituximab specifically 
targets the nephrotoxic Ig-producing cells, potentially 
inducing a lymphocyte subpopulation re-assessment 
(Figure 4).
ANTI-VIRAL THERAPY: THE POTENTIAL 
ROLE OF DIRECT ANTIVIRAL AGENTS
For more than a decade chronic HCV infection 
was mainly treated with pegylated interferon (PegIFN) 
associated with RBV, even though this regimen was poorly 
tolerated [44]. PegIFN/RBV therapy achieved eradication 
of infection in fewer than 50% of naıve patients with 
genotype 1 infection [44,45]. 
With regard to HCV-associated mixed 
cryoglobulinemia-associated vasculitis, PegIFN/RBV 
therapy was found to be most effective when combined 
with Rituximab. In a pilot study, Saadoun et al. treated 
16 consecutive, unselected refractory HCV-MC patients 
with RTX followed by antiviral therapy with Peg-IFN 
and RBV. Fifteen out of 16 patients showed clinical 
improvement with an acceptable safety profile [46]. In 
2010, Dammacco et al. and Saadoun et al. published two 
studies on the use of RTX with Peg-IFN+RBV according 
to a combined [38] or sequential [30] scheme, respectively. 
In these and other studies[30,31,38,47], combined therapy 
with RTX plus Peg-IFN+RBV resulted in better clinical 
response and higher cryoglobulin clearance than Peg-
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IFN+RBV alone. This could be due to the combination of 
cooperating mechanisms: viral eradication and depletion 
of the pathological B-cell clones. Furthermore, the clinical 
improvement obtained by adding RTX treatment could 
make patients who were previously non-eligible for anti-
viral therapy now eligible for treatment.
A better understanding of the HCV genome and 
structures paved the way for the development of direct-
acting antiviral agents (DAAs). Telaprevir and boceprevir 
were the first DAAs introduced in the clinical practice. 
Adding these protease inhibitors to PegIFN/RBV in 
naıve patients increased the rate of viral eradication to 
approximately 70% [48,49]; however, PegIFN/RBV is still 
needed since the use of DAAs as monotherapy may cause 
viral resistance [50,51]. With regard to HCV-associated 
mixed cryoglobulinemia with vasculitis, the combination 
of PegIFNalfa/ribavirin/protease inhibitor proved to be 
more effective than PegIFNalfa/ribavirin alone [52].
The new DAAs showed significant antiviral efficacy 
(>90% cure) and a good tolerance profile. Years of 
research have resulted in a very detailed understanding 
of the viral life-cycle of HCV, leading to new therapeutic 
strategies. HCV-RNA is bound by the translational 
machinery of the host cell to the viral internal ribosome 
entry site. Once internalized, the viral protein is processed 
into 3 structural and 7 nonstructural (NS) proteins [58]. 
The new drugs target the 3 nonstructural proteins: NS5A 
and NS5B RNA polymerase, the NS3 serine protease and 
its cofactor, NS4A. Telaprevir and Boceprevir represent 
the first-generation NS3/4A protease inhibitors but were 
approved for use only in combination with PegIFN/
RBV. Asunaprevir, paritaprevir and simeprevir are 
newly available DAAs. These inhibitors have improved 
pharmacologic profiles with fewer administrations and 
better tolerability. Despite the actual role of NS5A is 
still debated, this structure seems to be involved into 
the mechanism of viral replication and assembly [59]. 
Daclatasvir was the first NS5A inhibitor to be launched, 
[60], followed by ledipasvir [61] and ombitasvir [62]. 
Overall, these DAAs are effective against a wide spectrum 
of HCV genotypes [59]. However, those agents have a 
relatively low resistance threshold. Thus, to minimise the 
emergence of resistance mutations, their combined use is 
recommended. Two classes of NS5B inhibitors have been 
developed: nucleoside and nonnucleoside inhibitors. The 
nucleoside inhibitors have a particularly high thresholds 
to resistance due to variants in the active site, which is 
highly preserved across HCV genotypes, leading to a pan-
genotypic activity to DAAs [63]. To date, sofosbuvir is 
the most advanced DAAs: initially approved to be used 
in association with RBV for HCV infection (genotypes 2 
and 3), it is now the first all-oral, PegIFN-free regimen. 
Subsequenlty, sofosbuvir was approved for a combined 
use with simeprevir (NS3/4A serine protease inhibitor) 
or with ledipasvir (NS5A inhibitor). Beclabuvir and 
dasabuvir are non-nucleoside inhibitors of NS5B which 
recognize sites other than the active site and interfere with 
HCV viral elongation [64-66]. 
Multidrug regimens are combinations of an NS3/4A 
inhibitor, an NS5A inhibitor and a non-nucleoside NS5A 
inhibitor. A full 3D treatment regimen achieves an SVR 
rate of >95 percent when administered for 12 weeks to 
naıve patients, and >90 in prior non-responders. 
DAAs are expected to modify both the incidence 
of vasculitis resulting from a prolonged history of HCV 
infection and the therapeutic algorithms in the early stages 
of the disease. However, these agents do not possess the 
immunomodulatory effects of the interferons. They likely 
do not interfere with the pathogenesis of MC vasculitis 
nor effectively impact on the development of the immune-
mediated injury once the immune disorder is established. 
Besides, the uncertainty of their pharmacokinetics and 
safety in the presence of renal impairment requires some 
caution in their use in nephritic patients.
Limited evidence is currently available investigating 
the treatment with DAAs in patients with HCV-related 
MC [52-55], and results are difficult to interpret [56,57]. 
Makara[58] described the remission of multiorgan 
involvement and withdrawal of serum cryoglobulins 
after initiating DAA therapy as early as 4 weeks in a 40-
year old man with severe hepatitis C virus-associated 
cryoglobulinemia treated for 12 weeks with ombitasvir/
paritaprevir/ritonavir, dasabuvir and ribavirin. However, 
this patient had received 1,600 mg of Rituximab in 
four doses 5 months earlier. Rituximab probably 
contributed to the favourable response, in particular on 
the polyneuropathy which is known to require at least 6-9 
months to partially revert [29]. Details on the response 
profile of proteinuria were not available in that study. Sise 
at al. [56] showed that at 12 weeks patients with HCV-MC 
associated vasculitis had sustained virological response 
rate of 83% (10 out of 12 patients) for sofosbuvir-
based DAA regimens. These findings were statistically 
significantly higher than the historical control groups, 
which underwent treatment with pegylated interferon 
and ribavirin. The patients with glomerulonephritis (7 
out of 12) who were treated with DAA therapy showed 
a reduction in proteinuria and, concomitanly, an eGFR 
improvement. The reduction in proteinuria was particularly 
evident in the patients with a recent onset of proteinuria. 
However, by examining the paper in detail, it should be 
emphasised that during follow-up only 2 patients had a 
substantial amelioration of serum creatinine (one who 
was concomitantly treated with Rituximab and one who 
only had a clinical diagnosis because no biopsy had been 
performed). Changes were negligible in 4 patients, while 
serum creatinine increased over time in the remaining 
patient. About urinary abnormalities, the only patient who 
had nephrotic range proteinuria at baseline (and showed 
a decrease to non-nephrotic values) received Rituximab 
together with the DAAs. Another patient who showed 
a moderate reduction of proteinuria (from 1,574 to 800 
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mg/g sCr) was concomitantly treated with ustekinumab, 
an anti IL-12-23 monoclonal antibody, whose effects in 
proteinuric patients is presently unknown. Proteinuria 
decreased from 2,141 to 400 mg/g sCr in a patient who 
had not undergone biopsy. Of the remaining 4 patients, 
proteinuria was negative in one case, not determined in 
another, and only determined by urinalysis (1 and 3+, 
respectively) in 2 cases. 
Sollima et al.[59] treated 7 consecutive patients 
with HCV-associated mixed cryoglobulinemia vasculitis 
with new DAAs within an expanded access program. 
The patients showed a broad range of manifestations, 
including severe arthralgias, extensive purpura, peripheral 
neuropathy, skin ulcers and nephropathy. Nephropathy was 
the most frequent manifestation, presenting as a severe 
nephrotic syndrome, stages III-IV chronic kidney disease 
or both. Patients were treated with a variety of IFN-free 
DAA regimens, including ombitasvir/paritaprevir/ritonavir 
and dasabuvir, sofosbuvir plus ribavirin, sofosbuvir plus 
daclatasvir and sofosbuvir plus simeprevir, depending 
on HCV genotypes. Treatment was given for 12 weeks 
in five cases and 24 weeks in two. All patients achieved 
SVR at post-treatment week 12 (confirmed at week 24 in 
five of them, on a longer follow-up). Serum cryoglobulins 
were undetectable in 4 patients at the end of treatment 
but increased again in three during follow-up. At post-
treatment week 12, clinical response was observed in only 
2 patients. Specifically, the response was partial in one 
patient and complete in another who experienced vasculitis 
relapse despite HCV RNA still being undetectable. 
Thus, SVR to IFN-free antiviral therapy in severe HCV-
associated mixed cryoglobulinemia patients may lead to 
no clinical improvement. 
Cornella and coworkers [57] described a case 
series of 5 patients with genotype 1 chronic HCV-related 
hepatitis complicated by MC who received 24 weeks’ 
triple therapy with oral antiviral agents (boceprivir 
or telaprivir and sofosbuvir). Clearance of serum 
cryoglobulins was not present in any of these patients. 
Notably, a complete remission of MC associated 
with sustained virological response following a combined 
Peg-IFN+RBV+DAA (boceprevir)+Rituximab regimen 
was described by Urraro et al.[60].
Taken together these observations emphasise the 
role of DAAs in eradicating HCV infection even in mixed 
cryoglobulinemia patients, a subset that is less responsive 
to conventional antiviral treatment with Peg-IFN/RBV. 
However, more studies are needed to establish the ideal 
protocol and duration of therapy with DAAs for chronic 
HCV and coincident mixed cryoglobulinemia. 
Meanwhile, interest in Rituximab therapy in the 
most severe patients with mixed cryoglobulinemia 
remains unchanged. Besides its immunomodulatory effect, 
Rituximab also plays an important role by depleting CD19 
positive-B cells, known to be HCV reservoirs. Improving 
the effects on vasculitis treatment and HCV eradication 
using a combination of DAAs and Rituximab can be 
envisaged.
THERAPIES TARGETING ALTERNATIVE 
PATHWAYS
The use of other drugs, including thalidomide 
[61,62], lenalinomide [63], and bortezomib-based 
regimens [64, 65], may be useful in patients with type I 
cryoglobulinemia. Some anecdotal case reports describe 
successful approaches with abatacept [41] or tocilizumab 
[66]. B-cell activating factor (BAFF) blocking agents 
[67] and interleukin-2 agonists [68] may be promising 
future therapies. Again, the combination of these agents 
with DAAs could lead to parallel control of the vasculitic 
process and eradication of the viral trigger. 
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